Spruce Biosciences, Inc. announced completion of enrollment in its CAHmelia-204 clinical trial of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia . CAHmelia-204 is a.
Spruce Biosciences, Inc (NASDAQ:SPRB) Receives Consensus Recommendation of Buy from Analysts tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.
Spruce Biosciences, Inc (NASDAQ:SPRB) Receives $7 67 Consensus Target Price from Brokerages etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
Spruce Biosciences, Inc. (NASDAQ:SPRB – Get Free Report) shares dropped 4.8% during mid-day trading on Monday . The stock traded as low as $2.50 and last traded at $2.80. Approximately 213,448 shares changed hands during mid-day trading, a decline of 6% from the average daily volume of 226,250 shares. The stock had previously closed at […]